Moreover, combination therapies of everolimus plus fulvestrant or tamoxifen have also been proved feasible by PrE0102 and GINECO trials in postmenopausal patients with HR‐positive/HER2‐negative advanced breast cancer after treatment failure with endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.